Company Profile

Albireo Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its product, Bylvay, is for the treatment of pruritis in patients with progressive familial intrahepatic cholestasis (PFIC) ages three months or older and is authorized in Europe for the treatment of PFIC in patients ages six months or older. Its product candidate elobixibat is licensed for the treatment of chronic constipation and other functional diseases in Japan and other select markets in Asia. Its lead candidate for adult liver diseases, A3907, is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT) where systemic bioavailability has been demonstrated in preclinical and clinical studies. Its preclinical candidate for adult viral and liver diseases includes A2342.

Employees

Sector

Biotechnology & Medical Research

More about the company

03/03/23	CAC40: in green, gains over 2% on a weekly basis
03/03/23	CAC40: PMI and ISM data point to 22nd week of gains

03/03/23	CAC40: in green, gains over 2% on a weekly basis
03/03/23	CAC40: PMI and ISM data point to 22nd week of gains
03/03/23	CAC40: 7350 in sight if rates continue to ease
03/03/23	CAC40: breaks through 7300 pts after Bostic's comments
03/03/23	Ipsen: acquisition of Albireo Pharma finalized
03/03/23	French Drugmaker Ipsen Concludes Albireo Pharma Takeover	MT
03/03/23	Albireo Pharma, Inc. Announces Board Changes	CI
02/03/23	Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from NASDAQ Composite Index	CI
02/03/23	Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from S&P TMI Index	CI
02/03/23	Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from S&P Global BMI Index	CI
01/03/23	Ipsen Biopharmaceuticals, Inc. completed the acquisition of Albireo Pharma, Inc. from a group of shareholders.	CI
22/02/23	Ipsen Extends Tender Offer for Albireo Pharma as It Awaits US Antitrust Clearance	MT
22/02/23	Ipsen: extension of the deadline for its tender offer for Albireo Pharma

11/01/23	Guggenheim Downgrades Albireo Pharma to Neutral From Buy	MT
11/01/23	Cowen Downgrades Albireo Pharma to Market Perform From Outperform, Adjusts Price Target to $48 From $68	MT
11/01/23	Jefferies Downgrades Albireo Pharma to Hold From Buy, Adjusts Price Target to $42 From $49	MT
10/01/23	Baird Adjusts Price Target on Albireo Pharma to $45 From $55, Maintains Outperform Rating	MT
10/01/23	HC Wainwright Downgrades Albireo Pharma to Neutral From Buy, Price Target is $42	MT

03/03/23	ALBIREO PHARMA, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
15/02/23	Albireo Pharma, Inc. - FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay in Alagille Syndrome	AQ
14/02/23	ALBIREO PHARMA, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
14/02/23	FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille Syndrome	AQ
24/01/23	ALBIREO PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Albireo Pharma, Inc. - ALBO	BU

03/03/23	CAC40 : en vert, s'arroge plus de 2% en données hebdomadaires
03/03/23	CAC40 : vers la 22ème semaine de progression après PMI et ISM
03/03/23	CAC40 : 7350 en ligne de mire si la détente des taux continue
03/03/23	CAC40 : franchit les 7300 pts après les propos de Bostic
03/03/23	Les valeurs à suivre aujourd'hui à la Bourse de Paris - Vendredi 3 mars 2023

Biodel Inc Stock Nasdaq

Stocks

US09064M1053

Biotechnology & Medical Research

Latest news: Biodel Inc

Analysts' recommendations: Biodel Inc

Press Releases: Biodel Inc

News in other languages: Biodel Inc

Managers and Directors: Biodel Inc

Bio Therapeutic Drugs

Company Profile

Manager	Title	Age	Since
Christelle Huguet CEO	Chief Executive Officer	59	02/03/2023
Abla Abrial TRE	Treasurer	-	-
Jennifer Benenson SEC	Corporate Secretary	-	02/03/2023

Director	Title	Age	Since
François-Maurice Garnier BRD	Director/Board Member	64	02/03/2023
Aymeric Le Chatelier BRD	Director/Board Member	57	02/03/2023
Alan Sokaler BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.16B
ARGENX SE	-3.11%	-3.53%	+21.92%	+74.60%	57.39B
LONZA GROUP AG	+0.89%	-0.63%	+4.28%	+34.51%	47.64B
REVOLUTION MEDICINES, INC.	+0.36%	+0.81%	+342.39%	+742.40%	44.29B
IQVIA HOLDINGS INC.	-0.96%	-4.50%	+24.96%	+35.38%	42.5B
BEONE MEDICINES AG	-0.20%	-0.77%	+4.13%	+105.50%	40.71B
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+50.41%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	-2.68%	+2.92%	+29.63%	+19.50%	28.53B
BIONTECH SE	+0.05%	-1.64%	-8.14%	-11.37%	24.34B
Average	-0.23%	-0.59%	+53.09%	+127.23%	43.39B
Weighted average by Cap.	+0.12%	-0.84%	+57.49%	+136.81%

End-of-day quote Nasdaq
- ^USD	-